At ASCO 2025, several promising studies in pancreatic ductal adenocarcinoma (PDAC) were presented. In the neoadjuvant setting, the CASSANDRA trial compared the PAXG (nab-paclitaxel, capecitabine, ...
HealthDay on MSN
Main Pancreatic Duct Dilation Increases Odds for Neoplastic Progression in High-Risk Individuals
Main pancreatic duct (MPD) dilation without an apparent obstructing lesion is an independent risk factor for neoplastic ...
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced alignment with the U.S. Food and Drug ...
TipRanks on MSN
Oncolytics aligns with FDA on pelareorep study design
Oncolytics (ONCY) announced alignment with the FDA regarding the design of its pivotal study of pelareorep in combination with standard-of-care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback